Company Profile
Precigen Stock Price, News & Catalysts
- Ticker:
- PGEN
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
7.17 USD (-0.42%)
Close
Last updated: August 24, 2026
1.38B USD
Market cap
Why the stock is moving
As of Aug 24, 2026, PGEN closed down 0.42% at $7.17. No new same-company headline was identified in the current news window.
Company overview
Business overview
Precigen is a biotechnology company focused on gene and cell therapies, as well as engineered biologics. Its platform aims to create novel treatments across several disease areas.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Precigen sits in advanced biotechnology.
Business Model Characteristics
The company depends on platform validation, clinical data, and the ability to convert engineered biology into value.
Position Within the Biotechnology Landscape
Precigen is a platform biotech name whose stock reacts to progress in cell and gene therapy programs.
Future catalysts
- Precigen’s catalysts are PRGN-2012 and its UltraCAR-T platform, especially any update in recurrent respiratory papillomatosis or other immuno-oncology programs. The company needs to keep proving the platform can produce tangible clinical value.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Precigen (PGEN)?
Precigen (PGEN) most recently closed at 7.17 USD, a -0.42% move versus the previous session.
What is the market cap of Precigen (PGEN)?
Precigen currently has a market capitalization of 1.38B USD on BioPharmSignal.
What does Precigen do?
Precigen is a biotechnology company focused on gene and cell therapies, as well as engineered biologics. Its platform aims to create novel treatments across several disease areas.
On which exchange is PGEN stock listed?
Precigen (PGEN) is associated with NASDAQ, United States, Biopharma.
What is PRGN-2012?
Precigen’s catalysts are PRGN-2012 and its UltraCAR-T platform, especially any update in recurrent respiratory papillomatosis or other immuno-oncology programs.
Which conditions is Precigen targeting with PRGN-2012?
Precigen is associated with oncology, respiratory disease based on its company overview and current catalyst commentary.
How does Precigen describe recent progress with PRGN-2012?
Precigen’s catalysts are PRGN-2012 and its UltraCAR-T platform, especially any update in recurrent respiratory papillomatosis or other immuno-oncology programs.
What is Precigen?
Precigen is a biotechnology company focused on gene and cell therapies, as well as engineered biologics.